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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Ideal fluid management during surgery still poses a clinical dilemma
gauging the benefits and adverse effects. This randomized controlled trial compared the tissue
perfusion and coagulation profiles under clinically equivalent hydroxyethyl starch (HES 130/
0.4) and lactated Ringer’s solution (LR).
Methods: Eighty-four patients undergoing major abdominal surgery were randomized to receive
either HES or LR. Tissue perfusion parameters using heart rate, arterial blood pressure, central
venous pressure, cardiac index, stroke volume index, and central venous oxygen saturation were
measured at T0 (baseline), T1 (start of surgery), T2 (1 hour after start of surgery), and T3 (end of
surgery). Coagulation parameters using thrombelastography (TEG) were measured at T0 (base-
line), T4 (after 15 mL/kg fluid transfused), and T5 (24 hours after baseline).
Results: The total amount of fluid administrated was 1547.9  424.0 mL in HES group and
2303.1  1033.7 mL in LR group (p < 0.001). The parameters of tissue perfusion and TEG did
not differ significantly between groups at any time point except for a transient decrease in clotave no conflicts of interest relevant to this article.
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430 M.-H. Hung et al.kinetic and clot strength at T4 for HES group. There was no significant difference in blood loss
and consumption of blood products between the two fluids.
Conclusion: HES 130/0.4 is a more efficient intravascular volume expander to maintain tissue
perfusion than conventional crystalloid. Transient hypocoagulability induced by HES 130/0.4
does not warrant excessive blood loss and blood transfusion.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Perioperative fluid management for intravascular volume
deficits has been, and still is, the focus of much debate in
perioperative medicine.1 The debate has primarily focused
on the choice of the ideal fluid therapy with either crys-
talloid or colloid, or with either liberal or restrictive
amount of fluid.2e5 Large-volume crystalloid resuscitation
is associated with an increase in tissue edema, which
further jeopardizes tissue perfusion locally.6 On the
contrary, adverse effects of colloid therapy, such as
anaphylaxis and hemostatic impairment, are of concern.7
In a major abdominal surgery, patients commonly suffer
from absolute or relative intravascular volume deficits
because of preoperative fasting, gastrointestinal prepara-
tion, perioperative bleeding, exposure evaporation, third-
space losses, and vasodilation after general anesthesia.8
Hypovolemia during surgery has been associated with
intraoperative hemodynamic instability and tissue and/or
organ hypoperfusion. Therefore, adequate restoration of
intravascular volume is important to fulfill the nutritive role
of the circulation and to have beneficial outcomes on both
morbidity and mortality.
However, the optimal strategy remains controversial and
uncertain, and mostly depends on the dogma and belief of
the caring physician in spite of fluid therapy recommen-
dations.8 Recently, a new generation of hydroxyethyl starch
(HES) preparation (Voluven, 6% HES 130/0.4, Fresenius
Kabi GmbH, Bad Homburg, Germany) was introduced. It has
a lower mean molecular weight (130,000 Da), a lower
degree of molar substitution (0.4), and a narrower molec-
ular distribution profile; therefore, it is expected to have
less hemostatic interference than other HES prepara-
tions.1,9 However, interference with blood coagulation is
still the main obstacle to its adoption in perioperative fluid
management, especially in major surgery with potentially
significant bleeding and fluid shift.9 Therefore, this study
was designed to assess the efficacy of this new HES prep-
aration on tissue perfusion and coagulation in patients
undergoing major abdominal surgery, compared to that of
lactated Ringer’s solution (LR), by the concept of goal-
directed fluid management.10,11
Patients and methods
The study protocol was approved by our Research Ethics
Committees, and 84 adult patients undergoing elective
major abdominal surgery were included with their written
informed consent. Inclusion criteria for participation in the
study were loss of more than 500 mL blood during surgery
and admission to an intensive care unit after the surgery.Patients with cardiac insufficiency (New York Heart Asso-
ciation class IIIeIV), renal impairment (serum creatinine
>1.5 mg/dL), altered liver function (aspartate amino-
transferase >40 U/L, alanine aminotransferase >40 U/L, or
serum total bilirubin >2 mg/dL), preoperative anemia
(hemoglobin <10 g/dL), preoperative coagulation abnor-
malities (platelet count <100000/mL; international
normalized ratio >1.5), and known allergy to HES were
excluded from the study.
Anesthesia was induced with thiopental (4e6 mg/kg)
and fentanyl (3 mg/kg). Neuromuscular blockade was ach-
ieved with cisatracurium (0.2 mg/kg). Anesthesia was
maintained by incremental doses of fentanyl, cis-
atracurium, and 1e2% isoflurane titrated accordingly.
Mechanical ventilation was performed in all patients to
maintain arterial oxygen saturation of >95% and end expi-
ratory carbon dioxide concentration between 35 and
40 mmHg. Perioperative hemodynamic monitoring included
continuous measurement of electrocardiogram, arterial
blood pressure, and central venous pressure (CVP). Warm-
ing blanket device and fluid warmers were used to keep
patients normothermic (>36.0C). The patients were
managed perioperatively by anesthesiologists who were not
involved in the study and process of randomization.
Patients were randomly assigned to two groups by using
computer-generated randomnumbers. InHES group, patients
received intravenous infusion of 0.6%HES 130/0.4 throughout
the operation and, in LR group, LR was administered. Fluid
was given to maintain a predefined target of mean arterial
blood pressure (MAP) between 65 and 90 mmHg or CVP
between 8 and 12 mmHg. Vasopressor or inotropic agents
were addedwhen volume administration was not effective in
maintaining the predefined target blood pressure for 5
minutes.10,11 Maximum allowed doses for HES and LR infusion
were15and45mL/kg, respectively,which shouldbe followed
by other crystalloid infusion (e.g., 0.9% saline or 5% glucose
water) if necessary. Packed red blood cell (RBC) was trans-
fused when hemoglobin level dropped below 8 g/dL. At the
end of surgery, endotracheal tube was removed at the
discretion of the caring anesthesiologist. All patients were
sent to the intensive care unit and mechanical ventilation
continued if necessary. Intravenous morphine was used for
postoperative pain management for patients who requested
patient-controlled analgesia (PCA) prior to surgery. Those
without consent for PCA received intravenous fentanyl infu-
sion titrated as required in the intensive care unit.
Measurement of tissue perfusion
Tissue perfusion parameters were obtained by an uncali-
brated arterial pressure-based cardiac output monitor
Table 1 Demographic and perioperative data.
Variables HES group
(n Z 41)
LR group
(n Z 39)
p
Age (y) 48.0  10.7 50.4  8.7 0.276a
Sex (M/F) 23/18 25/14 0.616c
Weight (kg) 60.9  19.0 65.6  18.4 0.265a
Height (cm) 161.8  8.7 163.7  7.8 0.308a
Tissue perfusion and coagulation of HES 130/0.4 431(FloTrac-VigileoTM system, Edwards Lifesciences, Irvine, CA,
USA).12 Central venous oxygen saturation (ScvO2) was ob-
tained by a central venous oximetry catheter (PreSep,
Edwards Lifesciences).13 Data including heart rate (HR), MAP,
CVP, cardiac index (CI), stroke volume index (SVI), systemic
vascular resistance, and ScvO2 were recorded after induction
of anesthesia (T0, baseline), start of surgery (T1), 1 hour after
the start of surgery (T2), and at the end of the surgery (T3).Preoperative
hemoglobin (g/dL)
13.2  1.5 13.2  1.8 > 0.99a
Packed RBC
transfused (n)
1 5 0.201b
Duration of
surgery (min)
165.4  60.5 209.8  154.3 0.091a
Type of surgery (n)
UGI surgery 12 17 0.252c
LGI surgery 8 9
Hepatobiliary
surgery
21 13
Survivors 41 39 > 0.99b
Data are presented as mean  SD n.
HES Z hydroxyethyl starch; LGI Z lower gastrointestinal;
LR Z lactated Ringer’s solution; RBC Z red blood cell;
SD Z standard deviation; UGI Z upper gastrointestinal.
a From t test.
b From Fisher’s exact test.
c From chi-square test.Measurement of coagulation
A blood sample of 3 mL was drawn from an arterial catheter
into a citrated tube for coagulation test. Coagulation test
was performed by a modified thrombelastography (TEG) 14
(TEG 5000, Thrombelastograph Hemostasis Analyzer, Hae-
moscope Corporation, Niles, IL, USA) after induction of
anesthesia but prior to fluid administration (T0, baseline),
after 15 mL/kg of infused fluid in each study group (T4), and
24 hours after T0 (T5). The investigator responsible for the
TEG analysis was blinded to the study group. TEG reagent
(20 mL) containing calcium ion was added to 340 mL of kaolin-
activated and citrated whole blood in a disposable cup for
triggering the coagulation cascade. The cup was inserted in
a rotating metal cuvette heated to 37.0C. A piston with
rotated motion was dropped into the blood sample. An
electronic amplification system allowed the TEG tracing to
be recorded. Standard TEG variables including clotting time
(R), clot kinetics (K and alpha angle), and clot strength
(maximum amplitude, MA) were measured.Table 2 Intraoperative volume input and output.
Variables HES group
(n Z 41)
LR group
(n Z 39)
pa
6% HES 130/0.4
(mL)
999.1  369.3 Not infused NAStatistical analysis
Data are shown as mean  standard deviation unless other-
wise specified. Continuous, normally distributed data were
compared by paired and unpaired Student’s t-tests or anal-
ysis of variance for repeated measures. ManneWhitney rank
sum test was adopted whenever the analyzed data failed the
normality test using ShapiroeWilk test. The Bonferroni or
Tukey test was applied when multiple comparisons were
made for normally and non-normally distributed data,
respectively. All p values were two sided, p< 0.05 was taken
as significant, and all data were analyzed by SigmaPlot
software (version 12.0, Systat, San Jose, CA, USA).LR (mL) Not infused 1760.8  528.3 NA
0.9% saline/D5W
(mL)
548.8  443.6 542.3  733.7 0.271
Total amount
of fluid
administered
(mL)
1547.9  424.0 2303.1  1033.7 <0.001
Packed RBC (units
per group)
2 24 0.037
Blood loss (mL) 208.5  150.6 421.3  597.1 0.015
Urine output (mL) 304.8  224.7 546.6  418.5 <0.001
Data are presented as mean  SD unless otherwise noted.
D5W Z 5% dextrose water; HES Z hydroxyethyl starch;
LR Z lactated Ringer’s solution; NA Z not applied; RBC Z red
blood cell; SD Z standard deviation.
a From ManneWhitney rank sum test.Results
Eighty-four patients were enrolled in this study. Four
patients withdrew from this study because of their reluc-
tance to provide blood samples for TEG after surgery.
Therefore, 41 and 39 patients were included in HES and LR
group, respectively. Demographic characteristics of the
patients and perioperative datawere summarized in Table 1.
There were no significant differences between the two
groups with regard to age, sex, weight, height, preoperative
hemoglobin level, cases of packed RBC usage, and type of
surgery. All patients had a smooth recovery without
complications. The duration of surgery in LR group (mean
duration: 209.8 minutes) was longer than that in HES group
(165.4 minutes), but did not reach significance (pZ 0.091).Intraoperative volume input and output
Patients in HES group were infused with 999.1  369.3 mL
of HES 130/0.4 during the period of the study, whereas
those in LR group were administered 1760.8  528.3 mL of
LR (Table 2). Total amount of intravenous fluid transfused
was 1547.9  424.0 mL in HES group, which was significantly
432 M.-H. Hung et al.different from 2303.1  1033.7 mL transfused in LR group
(p < 0.001). Blood loss and urine output were both less in
HES group than in LR group, while amount of packed RBC
usage was significantly higher in LR group than in HES group
(Table 2).
Hemodynamics and tissue perfusion
Hemodynamics, including HR, MAP, CVP, CI, SVI, and ScvO2,
showed comparable courses in both groups (Table 3). SVI,
CI, and MAP were significantly increased in each group
compared to the baseline by a predefined goal-directed
fluid management.
TEG coagulation parameters
All data in TEG analysis were within normal ranges at any
time of the study (Table 4). TEG data at baseline was
comparable between groups. After infusion of 15 mL/kg of
HES 130/0.4 solution (T4), both clot kinetics and clot
strength showed significant difference compared to the
baseline(T0) (K: p Z 0.002; alpha angle: p Z 0.003; MA:
p < 0.001), which was compatible with relative hypo-
coagulation in TEG. On the contrary, clot kinetics at T4 in LR
group revealed an increase in clot kinetics with decreased KTable 3 Data of hemodynamics.
Variables T0 T1
HR (bpm)
HES 72.4  12.5 71.4  12.5
LR 70.5  12.0 70.5  14.0
MAP (mmHg)
HES 75.6  12.5 86.5  14.3*
LR 72.4  17.7 87.8  17.1*
CVP (mmHg)
HES 7.0  2.6 7.4  3.1
LR 7.2  3.2 7.8  3.1
CI (L/min/m2)
HES 2.8  0.8 3.0  0.7
LR 2.4  0.6 2.8  0.7*
SVI (mL/m2)
HES 37.6  7.0 42.3  8.1*
LR 34.2  6.3 39.6  9.0*
SVR (dyne/s/cm5)
HES 1265.2  234.1 1316.7  249.7
LR 1287.5  250.3 1406.0  257.0*
ScvO2 (%)
HES 84.9  5.0 85.3  4.8
LR 83.7  4.2 84.5  5.4
Data are presented as mean  SD.
*p < 0.05 compared with baseline (T0).
ANOVA Z analysis of variance; CI Z cardiac index; CVP Z central
LR Z lactated Ringer’s solution; MAP Z mean arterial pressure; ScvO
SVI Z stroke volume index; SVR Z systemic vascular resistance; T0 Z
surgery; T3 Z end of surgery.
a From one-way ANOVA and multiple-comparison procedures, whichtime and increased alpha angle (K: pZ 0.024; alpha angle:
p Z 0.046). Therefore, the ultimate strength of clot (G
index) was significantly different between groups at T4
(6.6  2.2 vs. 7.8  2.3, p < 0.001). All TEG coagulation
parameters returned to the baseline 24 hours later (T5).
Discussion
In this study, the effects of intravascular fluid therapy with
a new HES solution (Voluven, 6% HES 130/0.4) or LR on
tissue perfusion and coagulation were investigated in
patients undergoing major abdominal surgery. By using
predefined cardiovascular variables (e.g., MAP and CVP) as
targets to adjust the amount of fluid transfused,10,11 HES
130/0.4 was shown to be a more efficient intravascular
volume expander than LR, with less amount needed to
maintain the tissue perfusion parameters, including HR,
MAP, CI, SVI, and ScvO2. However, these two groups showed
significant difference with regard to coagulation status in
TEG (K time, alpha angle, MA, and G index) after adminis-
tration of 15 mL/kg of either HES or LR in comparison with
the baseline and also between groups in different direc-
tions, i.e., mildly hypocoagulable in HES group and mildly
hypercoagulable in LR group (Fig. 1). After 24 hours, the
coagulation changes returned to baseline in both groups.T2 T3 pa
70.5  11.7 70.4  13.4 0.387
70.6  14.8 71.8  12.6 0.821
83.9  9.3* 81.5  10.7* <0.001
81.8  12.2* 80.5  11.5* <0.001
9.0  2.9* 8.9  3.0* <0.001
7.8  3.6 7.2  3.3 0.554
3.0  0.5* 3.0  0.4* 0.004
2.8  0.7* 2.8  0.6* <0.001
42.8  8.1* 43.4  7.8* <0.001
39.8  6.7* 39.1  8.1* <0.001
1296.2  289.6 1260.5  259.2 0.085
1290.1  265.8 1311.3  258.5 0.002
85.1  4.8 85.5  4.8 0.716
84.3  5.5 84.2  5.9 0.908
venous pressure; HES Z hydroxyethyl starch; HR Z heart rate;
2 Z central venous oxygen saturation; SD Z standard deviation;
baseline; T1 Z start of surgery; T2 Z 1 hour after the start of
were performed if p < 0.05.
Table 4 Data of thromboelastography.
Variables T0 T4 T5 p a
R (min)
HES 5.7  3.4 5.5  2.4 5.5  2.2 0.404
LR 5.3  3.3 5.0  2.0 5.2  1.9 0.368
K (min)
HES 2.3  1.2 2.4  0.9*,y 2.3  1.0 0.002
LR 2.2  1.0 1.9  0.8* 2.1  1.0 0.024
Alpha angle ()
HES 62.7  11.2 60.4  9.1*,y 61.2  9.6 0.003
LR 62.3  9.8 65.5  8.1* 63.2  8.7 0.046
MA (mm)
HES 57.8  9.1 55.4  7.9*,y 58.4  8.7 <0.001
LR 57.9  7.9 59.7  7.5 59.5  5.5 0.176
G (kd/s)
HES 7.5  3.1 6.6  2.2*,y 7.5  2.5 <0.001
LR 7.3  2.4 7.8  2.3 7.6  1.6 0.304
Data are presented as mean  SD.
*p < 0.05 compared with baseline (T0).
yp < 0.05 between HES and LR groups.
ANOVA Z analysis of variance; G Z ultimate strength of clot;
HES Z hydroxyethyl starch; K Z time to specific strength of
clot; LRZ lactated Ringer’s solution; MAZ maximal amplitude
of clot; R Z reaction time of clot formation; SD Z standard
deviation; T0 Z baseline; T4 Z after 15 mL/kg of infused
solution; T5 Z 24 hours after baseline (T0).
a From one-way ANOVA and multiple-comparison procedures,
which were performed if p < 0.05.
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transfusion of 15 mL/kg of HES 130/0.4, the amount of blood
loss during the surgery was contrarily lower than in patients
transfused with clinically equal amount of LR (208.5 150.6
vs. 421.3  597.1 mL, pZ 0.015). Blood products were also
transfused more in LR group. Specifically, three patients in
LR group suffered from intraoperative blood loss of more
than 1000 mL, who were transfused with 16 units of RBCs.
Review of the TEG data of these three patients did not reveal
any significant coagulopathic condition, and operation
records also showed surgical difficulties with moderate to
severe intra-abdominal adhesion and prolonged surgical
time. A post hoc analysis after excluding these three patients
still revealed more amount of blood loss in patients trans-
fused with LR, but it was not statistically different. One may
argue that the operation time was longer in the LR group
(209.8 154.3 vs. 165.4 60.5 minutes, 95% CI: 96.1 toe7.3
minutes) and, therefore, blood loss increased. However,
considering the fact that all the data from TEG analysis
during the study period were within normal ranges at any
time point, these TEG findings in HES group may not be
clinically relevant in aspects of coagulopathy associated
with fluid therapy and may not warrant excessive blood loss
and blood transfusion by HES 130/0.4.
A hypercoagulable state after surgery is a quite common
phenomenon and formed the basis for prophylactic
management of perioperative thromboembolism.15 While
some suggest that surgery and stress response trigger the
enhancement in coagulation by stimulating the release ofprocoagulants into the systemic circulation, Ruttmann and
his colleagues16e19 have demonstrated in serial studies that
hemodilution per se is the most probable cause of post-
operative hypercoagulability. Administration of crystalloid
fluid (i.e., LR or 0.9% saline) results in an imbalance
between the naturally occurring anticoagulants and acti-
vated procoagulants, thus leading to the enhanced coagu-
lation.17 However, this effect appears to be modulated by
infusion of HES, which has been demonstrated to induce
a von Willebrand-like syndrome with decreased factor VIII
coagulant activity, and a von Willebrand factor antigen and
factor VIII-related ristocetin cofactor,9,20,21 thus decreasing
platelet adhesion capacity by blocking platelet membrane
receptor proteins GPIb and GPIIb/IIIa.22 New HES 130/0.4
with lower molecular weight and a lower molar substitution
has demonstrated to have less or even negligible negative
effects on coagulation, compared to its preceding similar
products, such as HES 450/0.7 and HES 200/0.6.1,9,22,23 Our
TEG data showed that a relative hypercoagulable state was
observed in the LR group while a relative hypocoagulable
state was observed in the HES group (Fig. 1). It is of interest
that coagulability returned to its baseline in either group 24
hours after surgery. A similar result has also been demon-
strated previously.17 Considering the populations at risk of
occlusive vascular events after surgery, enhancement of
coagulation by crystalloid fluid should not be overlooked.17
Since transfusion of HES 130/0.4 is not associated with
increased blood loss and is demonstrated to attenuate
hemodilution-induced enhancement of coagulation, it may
be suggested for patients with increased risks of perioper-
ative thromboembolism on the balance of hemostatic
interferences.17
This study has several limitations. One is the choice of
treatment target for fluid therapy. We used conventional
targets such as MAP and CVP instead of functional hemo-
dynamic variables, such as pulse-pressure variation, or
mixed venous oxygen saturation mostly adopted in goal-
directed fluid therapy.10,11 In the meanwhile, the main
indicators of tissue perfusion in this study were CI and
ScvO2, which are indicative of systemic tissue perfusion
rather than microcirculatory tissue perfusion.11e13 Since
a marked increase in systemic blood flow does not guar-
antee a concurrent increase in regional blood flow such as
intestinal blood flow, difference in specific tissue perfusion
may still exist, but it could not be detected by our methods.
Lang et al24 reported that colloid administration resulted in
an increased skeletal muscle oxygen tension in patients but
administration of LR did not. Mythen and Webb25 found
improved gastric mucosa pH and outcome in patients
receiving goal-directed administration of colloids compared
with control patients. It is our goal to adopt a conventional
target that can be accessible to every surgical patient and
to compare the efficacy of the HES 130/0.4 as an intra-
vascular volume expander on tissue perfusion with that of
LR, which is more reflective of our everyday practice.
We tested the coagulation state after transfusion of
15 mL/kg of either HES 130/0.4 or LR, which was estimated
to cause a 20e25% effect of hemodilution in our partici-
pants and was relatively restrictive in amount, compared to
the daily allowance of HES 130/0.4 (50 mL/kg/d).26 It was
decided based on our experiences regarding the amount of
intravenous fluid supplement needed in most major
Figure 1 Changes in clotting time (R), clot kinetics (K, alpha angle), and clot strength (MA) using TEG. Data are presented as
mean  standard error. *p < 0.05 different from baseline data. HESZ hydroxyethyl starch; KZ time to specific strength of clot;
LRZ lactated Ringer’s solution; MAZ maximal amplitude of clot; RZ reaction time of clot formation; T0Z baseline; T4Z after
transfusion of 15 mL/kg of either HES 130/0.4 or LR; T5 Z 24 hours after baseline.
434 M.-H. Hung et al.abdominal surgery. Although our TEG data also showed
a hypercoagulable state in the LR group, further hemodi-
lution (50e60%) may compromise blood coagulation due to
excessive hemodilutional coagulopathy.23
In summary, we demonstrated that HES 130/0.4 is
a more efficient intravascular volume expander to maintain
tissue perfusion than conventional crystalloid, LR. Although
clot kinetics and strength (K, alpha angle, and MA) were
mildly impaired after transfusion of 15 mL/kg of HES130/
0.4, it was not associated with clinically significant bleeding
during surgery and hence with the need of blood trans-
fusion. The transient hypocoagulability was recovered
within 24 hours after surgery.
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